GxP Vigilance + AI

01/04/2026

Are your validation records built to explain risk, or just to show testing happened?

That’s the practical shift from CSV to CSA. For AI-enabled trial systems, teams need risk classification, human oversight, version control, and lifecycle monitoring before the next inspection asks for it.

https://gxpvigilance.com.au/csv-to-csa-clinical-trial-teams-ai-age/

11/03/2026

Have you checked what recent regulatory updates mean for your systems?

Recent updates from TGA, EMA, FDA and MHRA highlight changes in safety reporting, clinical trials and real-world evidence oversight.

These are the areas inspectors often ask about first.

A curated global regulatory intelligence briefing covering TGA, Medsafe, EMA, FDA and MHRA developments affecting pharmacovigilance, clinical trials, GMP oversight, safety reporting and regulatory

09/03/2026

Are you actually ready for AI in a regulated workflow, or just under pressure to move? In GxP, readiness means documented intended use, human oversight, traceability, and records that hold up in an audit. Start narrower. Build the governance first.

AI readiness in GxP: use this ANZ-focused decision framework to assess governance, ALCOA+ data integrity, validation, and human oversight before deploying AI in regulated workflows. Reduce inspection risk, meet TGA and EMA expectations, and choose the right pilot scope

16/02/2026

AI can support pharmaceutical documentation—but only under clear GMP controls.

From drafting SOPs to monitoring regulatory updates, AI adds value when human review, validation, and audit trails are in place. Annex 22 makes it simple: AI assists, humans approve, systems record.

Smart governance turns AI into a compliance strength, not a risk.

Practical guidance for embedding AI in pharmaceutical documentation while maintaining GMP compliance, audit trails, and human

13/02/2026

Artificial intelligence is moving from pilot projects to validated, operational use across the pharmaceutical industry. But under GxP, AI requires risk-based validation, continuous monitoring, and qualified human oversight. We explain where AI is truly used—and what quality and regulatory professionals must consider before implementation. Read more:

A practical guide to artificial intelligence in pharmaceutical operations—what it is, where it's used, and what regulated teams need to

09/02/2026

Pharmacovigilance literature monitoring has reached a turning point. With over 1.5 million new publications each year, AI is no longer optional—it’s operationally essential. When properly validated and governed, AI delivers efficiency without compromising compliance, auditability, or sponsor accountability in line with ICH E6(R3) and TGA expectations.

AI-enabled literature monitoring achieves 97% sensitivity while reducing pharmacovigilance workload by 40-50%. This guide covers regulatory requirements, validation expectations, and human oversight

08/02/2026

Submitting a Risk Management Plan to the TGA is more than reusing an EU RMP. Australian submissions require local context, an Australian-Specific Annex, and ongoing lifecycle maintenance. Understanding how the TGA evaluates RMPs helps sponsors avoid findings and build proportionate, effective safety systems from day one.

How Australian sponsors adapt EU Risk Management Plans with a local annexure to meet TGA expectations and protect patient

08/02/2026

What does a pharmacovigilance consultant actually do in Australia—and how is AI changing the role? From TGA compliance to patient safety oversight, consultants bridge regulation and practice. As automation grows, human judgment, validation, and strategic oversight are more critical than ever.

Understand who Australian pharmacovigilance consultants are, what drives them, and how AI reshapes their

02/02/2026

Your CRO executes the work. You retain the accountability.

ICH E6(R3) makes this explicit: sponsors cannot outsource responsibility for quality and data integrity. If an auditor asks how you maintained oversight of delegated activities, can you produce the evidence?

New article explains what sponsors must understand.

Understand sponsor accountability for quality management systems in Australian clinical trials under TGA requirements and ICH

26/01/2026

Ever wondered what makes a strong GCP auditor in Australia?
This article explains the skills, experience, and judgement that matter beyond ticking boxes.

Discover what defines a GCP auditor in Australia—the qualifications, regulatory foundations, mindset, and continuous learning essential for effective clinical trial